drugset
drugset / Trial / NCT04665856

Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer

NCT04665856 ↗

Phase 3 Active not recruiting 123 enrolled Hoffmann-La Roche
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this multicenter study in China is to evaluate the safety and efficacy of tiragolumab plus atezolizumab and carboplatin and etoposide (CE) compared with placebo plus atezolizumab and CE in participants with untreated extensive-stage small cell lung cancer.

Timeline

Start
2020-12-21
Primary completion
2023-08-31
Completion
2026-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Tiragolumab Monoclonal antibody 600 mg Intravenous
Background Atezolizumab Monoclonal antibody 1200 mg Intravenous
Background Carboplatin Small molecule 5 unknown Intravenous
Background Etoposide Small molecule 100 mg/m2 Intravenous

Indications

small cell lung carcinoma